Efficacy and safety of NT 201 for upper limb spasticity of various etiologies--a randomized parallel-group study
- PMID: 20456248
- DOI: 10.1111/j.1600-0404.2010.01354.x
Efficacy and safety of NT 201 for upper limb spasticity of various etiologies--a randomized parallel-group study
Abstract
Objective: To assess efficacy and safety of two dilutions of botulinum neurotoxin type A NT 201 (Xeomin®) in patients with upper limb spasticity of diverse etiology.
Methods: Changes in functional disability and muscle tone from baseline to week 4 after NT 201 treatment.
Results: One hundred ninety-two patients with stroke, brain injury, multiple sclerosis, or cerebral palsy were randomized to either 50 or 20 U/ml NT 201 dilutions. The maximum total NT 201 dose was 495 units. Four weeks post-injection, a ≥ 1-point reduction was observed on the Disability Assessment Scale in 57.1%, and on the Ashworth scale in ≥ 62.2% of patients. The 20 U/ml NT 201 dilution was non-inferior to the 50 U/ml NT 201 dilution. Global improvement was rated high by patients (80.2%) and investigators (89.0%).
Conclusions: NT 201 improved functional disability and muscle tone and was well tolerated in patients with upper limb spasticity of diverse etiology in both dilutions.
© 2010 John Wiley & Sons A/S.
Similar articles
-
Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.Clin Neuropharmacol. 2009 Sep-Oct;32(5):259-65. doi: 10.1097/WNF.0b013e3181b13308. Clin Neuropharmacol. 2009. PMID: 19644361 Clinical Trial.
-
Long lasting benefits following the combination of static night upper extremity splinting with botulinum toxin A injections in cerebral palsy children.Eur J Phys Rehabil Med. 2009 Dec;45(4):501-6. Epub 2009 Jan 21. Eur J Phys Rehabil Med. 2009. PMID: 20032908 Clinical Trial.
-
Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.J Rehabil Med. 2011 May;43(6):486-92. doi: 10.2340/16501977-0796. J Rehabil Med. 2011. PMID: 21533328 Clinical Trial.
-
Common Etiologies of Upper Extremity Spasticity.Hand Clin. 2018 Nov;34(4):437-443. doi: 10.1016/j.hcl.2018.06.001. Epub 2018 Aug 18. Hand Clin. 2018. PMID: 30286958 Review.
-
[Spasticity and botulinum toxin in 2003. An update].Neurochirurgie. 2003 May;49(2-3 Pt 2):265-70. Neurochirurgie. 2003. PMID: 12746701 Review. French.
Cited by
-
Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.Neurol Int. 2012 Jun 14;4(2):e8. doi: 10.4081/ni.2012.e8. Epub 2012 May 29. Neurol Int. 2012. PMID: 23139852 Free PMC article.
-
Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis.Toxins (Basel). 2023 Dec 29;16(1):19. doi: 10.3390/toxins16010019. Toxins (Basel). 2023. PMID: 38251237 Free PMC article.
-
A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.J Rehabil Med. 2021 Jan 1;53(1):jrm00134. doi: 10.2340/16501977-2753. J Rehabil Med. 2021. PMID: 33057730 Free PMC article.
-
Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis.Toxins (Basel). 2021 Dec 11;13(12):887. doi: 10.3390/toxins13120887. Toxins (Basel). 2021. PMID: 34941725 Free PMC article.
-
Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA.Health Qual Life Outcomes. 2020 Mar 4;18(1):51. doi: 10.1186/s12955-020-01304-4. Health Qual Life Outcomes. 2020. PMID: 32131842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
